FDA Panel Backs NPS Pharma’s Gattex But Questions Registry Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
A post-approval registry for the short bowel syndrome drug needs to be rigorously designed and enroll a large proportion of patients in the orphan indication if it is to provide useful information about the drug’s long-term risks, members of FDA Gastrointestinal Drugs Advisory Committee said.
You may also be interested in...
NPS Looks To Repeat Success At FDA AdCom With Second Orphan Drug
Endocrinoloigc and Metabolic Drugs Advisory Committee will weigh in on Natpara for hypoparathryodism Sept. 12.
NPS Pharma’s REMS For Gattex Will Face FDA Panel Scrutiny
In briefing documents released ahead of the Oct. 16 Gastrointestinal Drugs Advisory Committee review, FDA suggests there is room for improvement in NPS’ communication plan for the short bowel syndrome treatment teduglutide to convey serious risks about malignancy and polyp growth and GI obstruction.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.